Full-Time

VP – Clinical Operations Excellence

Confirmed live in the last 24 hours

Relay Therapeutics

Relay Therapeutics

201-500 employees

Biotech company focused on drug discovery

Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary

You match the following Relay Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 10+ years of experience in the biopharma or CRO industry with a thorough understanding of clinical study processes
  • Strong and current knowledge in Good Clinical Practices and ICH Guidelines and the application to the conduct of clinical studies
  • Successful experience from at least one fast-paced entrepreneurial biotech company
  • Proactive problem solver who identifies solutions to problems before they arise
  • Recognized as a clinical operations expert with a track record of success and innovative program execution
  • Strategic planning, attention to detail, and an analytical approach to problem solving
  • Ability to mentor and develop talent in the organization
Responsibilities
  • Build, deploy and maintain all elements of a Risk-Based Quality Management (RBQM) approach in accordance with ICH E6R2 requirements for all clinical trials
  • Define the 'Relay Way' of executing clinical studies and implement a CRO-partnership model
  • Define standard expectations and ways of working (i.e. Operations Manual)
  • Lead the vendor Joint Oversight Committees (JOCs) in partnership with ClinOps Leads and CBO
  • Define, implement and report measurable functional parameters framework metrics (OKMs/KPI/KRIs) for internal and external stakeholders
  • Lead the Vendor Governance efforts
  • Partner with CBO and QA to ensure clear process for vendor qualification and maintenance
  • Participate in preparation for vendor audits, review reports, ensure resolution of findings
  • Oversee eTMF team for all Relay TX Trials
  • Ensure Relay review and oversight of Quality Events (QE) resolution with the vendor
  • Evaluate needs for CDO team training and either source training or develop in-house
  • Lead lessons learned initiatives
  • Oversee training compliance across Precision Medicines
  • Drive the creation, evaluation and delivery of tools, templates, new systems, technologies, and guidance for best practice
  • Oversee new SOP (WI, Form, Template) creation for CDO-owned SOPs
  • Oversee the periodic review of CDO-owned QDs and cross-functional SOPs

Relay Therapeutics focuses on drug discovery by emphasizing the movement of proteins in its research. The company uses its Dynamo™ platform, which integrates experimental and computational methods, to identify and develop new drugs, particularly for complex diseases that are hard to treat with current therapies. This platform enables Relay to target proteins that have previously been difficult to address, expanding treatment options in areas like precision oncology and genetic diseases. Unlike many competitors, Relay's approach is centered on understanding protein dynamics, which allows for more effective drug development. The company's goal is to create impactful medicines for patients, and it is engaged in clinical trials to ensure the safety and effectiveness of its drug candidates.

Company Size

201-500

Company Stage

IPO

Total Funding

$535M

Headquarters

Cambridge, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery complements Relay's computational techniques, enhancing drug development.
  • Quantum computing integration could boost Dynamo's capabilities in drug discovery.
  • Rising personalized medicine trend aligns with Relay's precision medicine focus.

What critics are saying

  • Increased competition from VantAI threatens Relay's market position.
  • Layoffs may impact Relay's operational efficiency and research progress.
  • Reliance on public offerings suggests potential financial instability for Relay.

What makes Relay Therapeutics unique

  • Relay's Dynamo platform targets previously undruggable proteins, expanding treatment possibilities.
  • Focus on protein motion places Relay at the forefront of innovative drug discovery.
  • Relay's precision oncology approach tailors treatments to individual genetic profiles.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, vision

Life, disability, & FSA

401k

Commuter benefits

Parental leave

Home office stipend

Tuition reimbursement

PTO

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

2%
Pattern of USA
Oct 7th, 2024
Job Reductions Update: Kaléo to Cut 58 Positions, Ongoing Layoffs at Stryker

Relay Therapeutics has announced it will be laying off about 10% of its workforce, impacting approximately 30 employees, as confirmed by a spokesperson in a statement to BioSpace.

Relay TX
Sep 18th, 2024
Relay Therapeutics Announces Pricing of Public Offering of Common Stock | Relay Therapeutics

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten

GlobeNewswire
Sep 11th, 2024
Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Relay Therapeutics announces pricing of public offering of common stock.

Stock Titan
Sep 11th, 2024
Relay Therapeutics Announces Pricing of Public Offering of Common Stock | RLAY Stock News

Relay Therapeutics announces $200M public offering of 28.5M shares at $7 each. Learn how this biotech firm plans to use the funds and what it means for investors. Closing expected Sept 12.

Tech Times New York
Sep 9th, 2024
Relay Therapeutics Announces Proposed Public Offering of Common Stock

Relay Therapeutics announces proposed public offering of common stock.